Cannabis: One Year Post Legalization
Analyst at Echelon Wealth Partners, Doug Loe, speaks about investing the health care and biotechnology sectors after cannabis legalization
According to Doug Loe, the approach to investing in the health care and biotechnology sector has always been to focus on the medium and long term. Loe says, “We are mindful that short term returns are relevant for any diversified portfolio and nascent industries, such as the newly legalized medical cannabis market. This is one that is going to undergo some bumps on profitability as we move forward”. Loe believes that there will certainly be some pricing pressure on cannabinoids that have limited intellectual property that is ascribed to the natural products themselves.
This graph shows the number of venture capital cannabis deals in the US and Canada from 2014 to 2019.
